An overview of GLP-1 agonists and recent cardiovascular outcomes trials

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment’s ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia. Additionally, seven c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheahan, Kelsey H, Wahlberg, Elizabeth A, Gilbert, Matthew P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042958/
https://www.ncbi.nlm.nih.gov/pubmed/31801807
http://dx.doi.org/10.1136/postgradmedj-2019-137186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042958/
https://www.ncbi.nlm.nih.gov/pubmed/31801807
http://dx.doi.org/10.1136/postgradmedj-2019-137186

Ejemplares similares